Role of ADP in platelet aggregation at high shear

Studies in a patient with congenital defect of platelet responses to ADP

M. Cattaneo, M. L. Zighetti, R. Lombardi, P. Mannuccio Mannucci

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

The in vitro measurement of platelet aggregation (PA) at the high shear levels that can be found in the microcirculation may provide useful informations on primary haemostasis, which is usually explored in vivo with the skin bleeding time (BT). PA at high shear requires von Willebrand factor (vWf) and the platelet glycoprotein (GP) complexes Ib/IX/V and IIb/IIIa; controversial results have been reported on its requirement of released adenosine diphosphate (ADP). Due to its dependence on vWf, PA at high shear may be affected by the vasopressin analogue DDAVP, which increases the plasma vWf levels and shortens the prolonged BT of patients with congenital or acquired defects of platelet function. We studied PA at high shear, BT and plasma vWf levels in a patient with congenital impairment of platelet responses to ADP before and after the i.v. infusion of 0.3 μg/kg DDAVP. Two methods to study PA at high shear were used: shear-induced PA (SIPA) and the filter aggregation test. With both methods, PA at high shear of the patient was impaired. The infusion of DDAVP increased plasma vWf levels, shortened the prolonged BT and potentiated PA at high shear of the patient. In conclusion, PA at high shear is impaired in a patient with congenital defect of platelet responses to ADP and prolonged BT and is potentiated by DDAVP. Our results suggest that released ADP plays an important role in PA at high shear and that potentiation of PA at high shear by DDAVP may be one mechanism by which the drug shortens the prolonged BT of patients with congenital or acquired defects of platelet function.

Original languageEnglish
Pages (from-to)826-829
Number of pages4
JournalBritish Journal of Haematology
Volume88
Issue number4
Publication statusPublished - 1994

Fingerprint

Platelet Aggregation
Adenosine Diphosphate
Blood Platelets
Bleeding Time
Deamino Arginine Vasopressin
von Willebrand Factor
Platelet Glycoprotein GPIb-IX Complex
Platelet Membrane Glycoproteins
Microcirculation
Hemostasis
Vasopressins
Skin

Keywords

  • Adenosine diphosphate
  • DDAVP
  • Platelet aggregation
  • Platelet function disorders
  • Shear stress
  • Von willebrand factor

ASJC Scopus subject areas

  • Hematology

Cite this

Role of ADP in platelet aggregation at high shear : Studies in a patient with congenital defect of platelet responses to ADP. / Cattaneo, M.; Zighetti, M. L.; Lombardi, R.; Mannuccio Mannucci, P.

In: British Journal of Haematology, Vol. 88, No. 4, 1994, p. 826-829.

Research output: Contribution to journalArticle

@article{7d83338736f940a4a5b45423434a2d32,
title = "Role of ADP in platelet aggregation at high shear: Studies in a patient with congenital defect of platelet responses to ADP",
abstract = "The in vitro measurement of platelet aggregation (PA) at the high shear levels that can be found in the microcirculation may provide useful informations on primary haemostasis, which is usually explored in vivo with the skin bleeding time (BT). PA at high shear requires von Willebrand factor (vWf) and the platelet glycoprotein (GP) complexes Ib/IX/V and IIb/IIIa; controversial results have been reported on its requirement of released adenosine diphosphate (ADP). Due to its dependence on vWf, PA at high shear may be affected by the vasopressin analogue DDAVP, which increases the plasma vWf levels and shortens the prolonged BT of patients with congenital or acquired defects of platelet function. We studied PA at high shear, BT and plasma vWf levels in a patient with congenital impairment of platelet responses to ADP before and after the i.v. infusion of 0.3 μg/kg DDAVP. Two methods to study PA at high shear were used: shear-induced PA (SIPA) and the filter aggregation test. With both methods, PA at high shear of the patient was impaired. The infusion of DDAVP increased plasma vWf levels, shortened the prolonged BT and potentiated PA at high shear of the patient. In conclusion, PA at high shear is impaired in a patient with congenital defect of platelet responses to ADP and prolonged BT and is potentiated by DDAVP. Our results suggest that released ADP plays an important role in PA at high shear and that potentiation of PA at high shear by DDAVP may be one mechanism by which the drug shortens the prolonged BT of patients with congenital or acquired defects of platelet function.",
keywords = "Adenosine diphosphate, DDAVP, Platelet aggregation, Platelet function disorders, Shear stress, Von willebrand factor",
author = "M. Cattaneo and Zighetti, {M. L.} and R. Lombardi and {Mannuccio Mannucci}, P.",
year = "1994",
language = "English",
volume = "88",
pages = "826--829",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "John Wiley & Sons, Ltd (10.1111)",
number = "4",

}

TY - JOUR

T1 - Role of ADP in platelet aggregation at high shear

T2 - Studies in a patient with congenital defect of platelet responses to ADP

AU - Cattaneo, M.

AU - Zighetti, M. L.

AU - Lombardi, R.

AU - Mannuccio Mannucci, P.

PY - 1994

Y1 - 1994

N2 - The in vitro measurement of platelet aggregation (PA) at the high shear levels that can be found in the microcirculation may provide useful informations on primary haemostasis, which is usually explored in vivo with the skin bleeding time (BT). PA at high shear requires von Willebrand factor (vWf) and the platelet glycoprotein (GP) complexes Ib/IX/V and IIb/IIIa; controversial results have been reported on its requirement of released adenosine diphosphate (ADP). Due to its dependence on vWf, PA at high shear may be affected by the vasopressin analogue DDAVP, which increases the plasma vWf levels and shortens the prolonged BT of patients with congenital or acquired defects of platelet function. We studied PA at high shear, BT and plasma vWf levels in a patient with congenital impairment of platelet responses to ADP before and after the i.v. infusion of 0.3 μg/kg DDAVP. Two methods to study PA at high shear were used: shear-induced PA (SIPA) and the filter aggregation test. With both methods, PA at high shear of the patient was impaired. The infusion of DDAVP increased plasma vWf levels, shortened the prolonged BT and potentiated PA at high shear of the patient. In conclusion, PA at high shear is impaired in a patient with congenital defect of platelet responses to ADP and prolonged BT and is potentiated by DDAVP. Our results suggest that released ADP plays an important role in PA at high shear and that potentiation of PA at high shear by DDAVP may be one mechanism by which the drug shortens the prolonged BT of patients with congenital or acquired defects of platelet function.

AB - The in vitro measurement of platelet aggregation (PA) at the high shear levels that can be found in the microcirculation may provide useful informations on primary haemostasis, which is usually explored in vivo with the skin bleeding time (BT). PA at high shear requires von Willebrand factor (vWf) and the platelet glycoprotein (GP) complexes Ib/IX/V and IIb/IIIa; controversial results have been reported on its requirement of released adenosine diphosphate (ADP). Due to its dependence on vWf, PA at high shear may be affected by the vasopressin analogue DDAVP, which increases the plasma vWf levels and shortens the prolonged BT of patients with congenital or acquired defects of platelet function. We studied PA at high shear, BT and plasma vWf levels in a patient with congenital impairment of platelet responses to ADP before and after the i.v. infusion of 0.3 μg/kg DDAVP. Two methods to study PA at high shear were used: shear-induced PA (SIPA) and the filter aggregation test. With both methods, PA at high shear of the patient was impaired. The infusion of DDAVP increased plasma vWf levels, shortened the prolonged BT and potentiated PA at high shear of the patient. In conclusion, PA at high shear is impaired in a patient with congenital defect of platelet responses to ADP and prolonged BT and is potentiated by DDAVP. Our results suggest that released ADP plays an important role in PA at high shear and that potentiation of PA at high shear by DDAVP may be one mechanism by which the drug shortens the prolonged BT of patients with congenital or acquired defects of platelet function.

KW - Adenosine diphosphate

KW - DDAVP

KW - Platelet aggregation

KW - Platelet function disorders

KW - Shear stress

KW - Von willebrand factor

UR - http://www.scopus.com/inward/record.url?scp=0028090198&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028090198&partnerID=8YFLogxK

M3 - Article

VL - 88

SP - 826

EP - 829

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 4

ER -